Digital Underinvestment in medtech threatens sector growth - EY Underinvestment in medical technology could threaten growth in the sector, according to a report by Ernst & Young (EY).
News Neumora laid low by depression trial failure The first of three phase 3 trials of Neumora's novel antidepressant navacaprant has ended in failure, wreaking havoc with its share price.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
